NCT06081699已完成1 期
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of TNP-2198 Capsules in Healthy Participants and the Effect of Food on the Pharmacokinetics of TNP-2198 Capsules in Healthy Participants
TenNor Therapeutics (Suzhou) Limited1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2019年5月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Adverse Events (AEs)
研究概览
简要总结
This was a single-center, randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety, tolerability, pharmacokinetics of single ascending dose and the food effect on the pharmacokinetics of TNP-2198 capsules after single dose oral administration in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Those signed the informed consent form and fully understood the study contents, process and possible adverse reactions before participation in the study;
- •Those are able to complete the study according to the requirements of the study protocol;
- •Those (including the partner) are willing to use effective contraceptives from the screening up to 6 months after the last dose of study drug;
- •Male and female subjects aged 18 to 55 years (inclusive);
- •Male subjects no less than 50 kg and female subjects no less than 45 kg. BMI (Body Mass Index= body weight (kg)/height^2 (m^2)): 18-28kg/m^2 (inclusive);
- •Health status: no clinically significant history of heart, liver, kidney, digestive tract, nervous system, respiratory system diseases, mental disorders or metabolic abnormalities;
- •Normal results or abnormal results without clinical significance in physical examinations and vital signs;
- •Clinical laboratory test results are within normal limits or abnormal but without clinical significance as judged by the investigator.
排除标准
- •Average daily consumption of more than 5 cigarettes within 3 months before the study;
- •History of hypersensitivity to study drug or its excipients, or allergic constitution (allergy to multiple drugs and food);
- •History of drug and/or alcohol abuse (mean consumption of ≥ 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of liquor, or 100 mL of wine);
- •Blood donation or massive blood loss (> 450 mL) within 3 months prior to screening;
- •Using any drug that changes liver enzyme activity within 28 days prior to screening;
- •Using any prescription drug, over-the-counter drug, any vitamin product, or herbal medicine within 14 days prior to screening;
- •Taking special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, or having other factors that affect drug absorption, distribution, metabolism, excretion, etc., within 2 weeks prior to screening;
- •Significant changes in diet or exercise habits recently;
- •Taking other study drugs or participating in other clinical studies within 3 months before taking the study drug;
- •With difficulty in swallowing or history of any gastrointestinal diseases that affect drug absorption;
- •With any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers;
- •Unable to tolerate standardized meal (two boiled eggs, one butter bacon toast, one box of fried potato chips, and one cup of whole milk) (only for subjects participating in the food effect study);
- •With clinically significant ECG abnormalities;
- •Female subjects who are lactating or have positive serum pregnancy result during the screening period, or have positive serum pregnancy result during the study;
- •With symptoms or previous history of cardiovascular, digestive, respiratory, urinary, neurological, hematologic, immunological, endocrine system diseases, tumor, or psychiatric diseases;
- •Clinically significant abnormalities in clinical laboratory tests, or other clinically significant findings (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immunological, psychiatric, or cardiovascular disease);
- •Positive viral hepatitis (including hepatitis B and C), HIV antibody, treponema pallidum antibody;
- •Acute illness or concomitant medication from the time of signing informed consent to the time of study medication;
- •Intake of chocolate, any caffeine- or xanthine-containing food or drink within 48 hours prior to administration of study drug;
- •Intake of any alcohol-containing products within 48 hours prior to administration of study drug;
- •Positive urine drug screening or history of drug abuse or drug addiction within the past 5 years;
- •Other conditions that, in the opinion of the investigator, make the patient participating in this study inappropriate.
研究组 & 干预措施
Single Ascending Doses Cohort 1
Experimental
TNP-2198 Capsules 50mg
干预措施: TNP-2198 (Drug)
Single Ascending Doses Cohort 2
Experimental
TNP-2198 Capsules 100mg
干预措施: TNP-2198 (Drug)
Single Ascending Doses Cohort 3
Experimental
TNP-2198 Capsules 200mg
干预措施: TNP-2198 (Drug)
Single Ascending Doses Cohort 4
Experimental
TNP-2198 Capsules 400mg
干预措施: TNP-2198 (Drug)
Single Ascending Doses Cohort 5
Experimental
TNP-2198 Capsules 600mg
干预措施: TNP-2198 (Drug)
Single Ascending Doses Cohort 6
Experimental
TNP-2198 Capsules 800mg
干预措施: TNP-2198 (Drug)
Single Ascending Doses Cohort 7
Experimental
TNP-2198 Capsules 1000mg
干预措施: TNP-2198 (Drug)
Food Effect Cohort 8
Experimental
TNP-2198 Capsules 200mg
干预措施: TNP-2198 (Drug)
Placebo Cohort 9
Placebo Comparator
Placebo
干预措施: TNP-2198 Placebo (Drug)
结局指标
主要结局
Percentage of Participants With Adverse Events (AEs)
时间窗: Day 1 to Day 4
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
次要结局
- Area Under the Plasma Concentration Versus Time Curve from 0 to the Last Measurable Concentration (AUC0-t)(Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration.)
- Maximum Observed Plasma Concentration (Cmax) of TNP-2198(Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration.)
- Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)(Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Tolerability of ILB-202HealthyNCT05843799ILIAS Biologics Inc.18
已完成
1 期
The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese VolunteersAcute Ischemic StrokeCerebral EdemaNCT05200728Jiangsu Simcere Pharmaceutical Co., Ltd.68
已完成
1 期
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male SubjectsHealthy SubjectsNCT04636983BioVersys SAS54
已完成
1 期
Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge ModelMalariaNCT03707041Medicines for Malaria Venture32
已完成
1 期
A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsHealthyNCT04976270Galapagos NV23